Skip to content
Screener

Total Revenue at other companies

Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
$317M+19.2%
Scilex Holding Company logo
Scilex Holding CompanySCLX
$8.61M+72.1%
AVN
AVNSAVNS
$182.2M+8.8%
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$177.38M+5.0%
Bioventus logo
BioventusBVS
$153.21M+3.8%
Organon logo
OrganonOGN
$1.46B-3.5%

Segments

By product

See full
Belbuca$57.67M+9.6%
Jornay PM$46.06M+41.2%
Xtampza ER$45.01M
Nucynta ER$15.72M-21.2%
Symproic and other$14.45M
Nucynta IR$14.36M-45.8%

By segment

See full
Segment$199.88M+6.3%

Other financials

Income statement

See full
Gross profit$110.3M+1.8%
Operating income$3.7M-89.5%
Net income-$15.1M-226%
EPS (diluted)-$0.46-235%

Balance sheet

See full
Cash & equivalents$150.4M+8.8%
Total debt$5.0M-19.8%
Total equity$311.9M+34.3%
Total assets$2.1B+34.1%

Cash flow

See full
Operating cash flow$71.3M-1.5%
CapEx$496.0K+663%
Free cash flow$70.8M-2.1%

Valuation

See full
Market cap$944.15M-1.3%
Enterprise value$798.74M-3.1%
P/E19.7×-6.7×
P/S1.2×-0.2×

Profitability

See full
Gross margin60%+3.3pp
Operating margin19.5%+1.1pp
Net margin5.9%+0.8pp
FCF margin40.6%+10.8pp

Returns & leverage

See full
Return on equity17.6%+1.4pp
Debt / equity0.0×
Current ratio-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:34 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053851
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Product revenues, net$199,878$188,000$393,398$365,757
Cost of product revenues
Cost of product revenues (excluding intangible asset amortization)26,63324,14347,43449,103
Intangible asset amortization62,95355,473118,426110,946
Total cost of product revenues89,58679,616165,860160,049
Gross profit110,292108,384227,538205,708
Operating expenses
Selling, general and administrative106,59473,637192,944150,060

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s total revenue?
Collegium Pharmaceutical, Inc. (COLL) reported total revenue of $199.88M in Q2 2026.
How has Collegium Pharmaceutical, Inc.'s total revenue changed year-over-year?
Collegium Pharmaceutical, Inc.'s total revenue increased by 6.3% year-over-year, from $188M to $199.88M.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s total revenue?
Over 4 years (2021 to 2025), Collegium Pharmaceutical, Inc.'s total revenue has grown at a 29.6% compound annual growth rate (CAGR), from $276.87M to $780.57M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Collegium Pharmaceutical, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude